Log in to search using one of your social media accounts:

 

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advan ced non-squamous non-small cell lung cancer (NSCLC). Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These d...
Source: Roche Media News - November 20, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advan ced non-squamous non-small cell lung cancer (NSCLC). Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These d...
Source: Roche Investor Update - November 20, 2017 Category: Pharmaceuticals Source Type: news

Osimertinib improves progression-free survival in Asian EGFR-mutated lung cancer patients
(European Society for Medical Oncology) Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 20, 2017 Category: Cancer & Oncology Source Type: news

Erlotinib Overdose Tied to Conjunctivitis
Findings in case study of man being treated for non - small - cell lung cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 17, 2017 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Emergency Medicine, Oncology, Ophthalmology, Pharmacy, Journal, Source Type: news

ALEX study shows alectinib 600 mg more effective than crizotinib in Asian cancer patients
(European Society for Medical Oncology) A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 17, 2017 Category: Cancer & Oncology Source Type: news

FDG-PET/CT could improve treatment for NSCLC patients
Using FDG-PET/CT, researchers in Italy have found a correlation between cell-free...Read more on AuntMinnie.comRelated Reading: Study questions value of CT scans after NCSLC surgery PET identifies cell mutations in NSCLC patients ASTRO: Negative PET/CT doesn't always mean dormant NSCLC SNMMI: FDG-PET can monitor immunotherapy for NSCLC (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 9, 2017 Category: Radiology Source Type: news

Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer
PT 107 showed improvement in overall survival and significant improvement in time to progression, as compared to control In non-squamous patients, the benefit of PT 107 in overall survival was striking and highly significant PT 107 was well tolerated... Biopharmaceuticals, Oncology Pique Therapeutics, cell vaccine, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 7, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa ® (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Source: Roche Media News)
Source: Roche Media News - November 7, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa ® (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Source: Roche Investor Update)
Source: Roche Investor Update - November 7, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche drugs for rare types of blood, lung cancers
(Reuters) - Roche Holding AG won U.S. approval to market its skin cancer drug Zelboraf for certain patients with Erdheim-Chester Disease, a rare type of blood cancer, and to market its drug Alecensa as a first choice of treatment for a subset of patients with non-small cell lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - November 6, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness
(Society of Nuclear Medicine and Molecular Imaging) Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC). In a study presented in the featured clinical investigation article of the November issue of The Journal of Nuclear Medicine, they used 18F-fluorodeoxyglucose (FDG) PET/CT imaging to show that the amount of cell-free tumor DNA circulating in the bloodstream correlates with tumor metabolism (linked to cancer aggressiveness), not tumor burden (amount of cancer in the body). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 6, 2017 Category: International Medicine & Public Health Source Type: news

FDA Approves Alecensa (alectinib) as First-Line Treatment for ALK-Positive Metastatic Non-Small Cell Lung Cancer
South San Francisco, CA -- November 6, 2017 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 6, 2017 Category: Drugs & Pharmacology Source Type: news

Incyte, AstraZeneca expand collaboration on potential lung cancer therapy
Incyte Corp. is expanding its clinical collaboration with MedImmune, AstraZeneca's global biologics research and development arm. As part of the expanded agreement, the two companies will evaluate the effectiveness and safety of a combination therapy — featuring one product from each company — in treating patients with non-small cell lung cancer. The phase-III study of the treatment pairing Incyte's investigational enzy me inhibitor called epacadostat with AstraZeneca's Imfinzi human monoclonal… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 31, 2017 Category: Biotechnology Authors: John George Source Type: news

Merck withdraws marketing application for Keytruda in Europe
(Reuters) - Merck& Co Inc said on Friday it had withdrawn its European application for Keytruda as a combination treatment for patients with an advanced stage of non-small cell lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Survival Improving in Early-Stage Lung Cancer Survival Improving in Early-Stage Lung Cancer
More patients with early-stage non-small cell lung cancer are now surviving at least 2 years after their diagnosis, thanks to increasingly sophisticated treatment techniques.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Survival Odds Improving for Lung Cancer Patients
Study of more than 65,000 people with stage 1 non-small-cell lung cancer found majority had surgery while 18% refused surgery or radiation. (Source: WebMD Health)
Source: WebMD Health - October 26, 2017 Category: Consumer Health News Source Type: news

NovoCure rises on Q3 EPS, sales beat
Shares in Novocure (NSDQ:NVCR) are on the rise today after the medical device maker topped revenue and losses-per-share expectations on Wall Street with its 3rd quarter earnings results. The St. Helier, N.J.-based company posted losses of $11.5 million, or 13¢ per share, on sales of $50.1 million for the 3 months ended September 30, seeing losses on the bottom-line shrink 65.8% while sales grew 131.2% compared with the same period during the previous fiscal year. Losses per share for the quarter came in under the 17¢ consensus on Wall Street, while sales beat the $43.6 million expectations on The Street. &ld...
Source: Mass Device - October 26, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup NovoCure Source Type: news

More early stage lung cancer patients survive the disease
(Elsevier) With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online today in The Annals of Thoracic Surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2017 Category: Cancer & Oncology Source Type: news

2 Things that Go Together: Yoga and Advanced Lung Cancer 2 Things that Go Together: Yoga and Advanced Lung Cancer
Participating in a yoga program while undergoing radiation therapy improved physical functioning and mental in NSCLC patients, and improved vitality in caregivers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 23, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Two Things That Go Together: Yoga and Advanced Lung Cancer Two Things That Go Together: Yoga and Advanced Lung Cancer
Participating in a yoga program while undergoing radiation therapy improved physical functioning and mental in NSCLC patients, and improved vitality in caregivers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 23, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Biomarkers for Selecting Lung Adenocarcinoma Therapy Biomarkers for Selecting Lung Adenocarcinoma Therapy
Review recent advances in diagnosis and treatment of advanced nonsquamous NSCLC.Journal of Oncology Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 23, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Drug yields high response rates for lung cancer patients with harsh mutation
(University of Texas M. D. Anderson Cancer Center) A targeted therapy resurrected by the Moon Shots Program ™ at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries a highly treatment-resistant mutation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 18, 2017 Category: International Medicine & Public Health Source Type: news

Study cites race and socioeconomic factors as influential in NSCLC patient survival rates
(International Association for the Study of Lung Cancer) New research found race and specific socioeconomic factors to have a significant influence on disparities in the survival rates of non-small cell lung cancer (NSCLC) patients. Dr. Yanyan Lou of the Mayo Clinic in the United States presented these findings today at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 16, 2017 Category: Cancer & Oncology Source Type: news

Treatment based On BRCA1 level does not increase survival of stage II/III NSCLC N+ resected patients
(International Association for the Study of Lung Cancer) Research shows that treating stage II and III non-small cell lung cancer (NSCLC) N+ resected patients with customized chemotherapy treatment based on their specific BRCA1 expression levels, as opposed to providing the standard treatment, did not increase overall survival rates among those patients who received individualized CT treatment. Dr. Bartomeu Massuti of Alicante University Hospital in Spain presented his findings today at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. (Source...
Source: EurekAlert! - Cancer - October 16, 2017 Category: Cancer & Oncology Source Type: news

CHMP recommends EU approval of Roche ’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC
Roche announced today that the European Union ’s (EU) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Alecensa® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCL C). (Source: Roche Media News)
Source: Roche Media News - October 13, 2017 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC
Roche announced today that the European Union ’s (EU) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Alecensa® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCL C). (Source: Roche Investor Update)
Source: Roche Investor Update - October 13, 2017 Category: Pharmaceuticals Source Type: news

Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - October 11, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Lilly's breast cancer drug fails to help lung patients
(Reuters) - Eli Lilly and Co said its recently approved breast cancer drug failed to meet a late-stage trial's main goal of improving overall survival in patients with non-small cell lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - October 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Lilly's lung cancer drug fails main goal of key study
(Reuters) - Eli Lilly and Co said its drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage trial, sending its shares down about 3 percent. (Source: Reuters: Health)
Source: Reuters: Health - October 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Lilly's lung cancer drug fails late-stage study
(Reuters) - Eli Lilly and Co said on Tuesday its drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - October 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Lung cancer research gets a breath of fresh air
(Wyss Institute for Biologically Inspired Engineering at Harvard) As reported in Cell Reports, a team at the Wyss Institute has leveraged its human Organs-on-Chips technology to develop human orthotopic lung cancer models using human lung small airway and alveoli chips. The study models central aspects of non-small cell lung cancer (NSCLC) in real time and high-resolution and offers a window on the biological tumor complexities. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2017 Category: Cancer & Oncology Source Type: news

EMA accepts marketing application for Imfinzi to treat NSCLC patients
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for AstraZeneca and MedImmune ’s Imfinzi (durvalumab) to treat patients with locally advanced, unresectable non-small-cell lung cancer (NSCLC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 9, 2017 Category: Pharmaceuticals Source Type: news

Dacomitinib Improves Survival in Non-Small-Cell Lung Cancer Dacomitinib Improves Survival in Non-Small-Cell Lung Cancer
Dacomitinib as first-line treatment improves progression-free survival, compared with gefitinib, in patients with EGFR-mutation-positive non-small-cell lung cancer (NSCLC), according to results from the international ARCHER 1050 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Nodal Staging Quality Linked to Lung Cancer Survival Nodal Staging Quality Linked to Lung Cancer Survival
The quality of pathologic nodal staging is associated with survival in patients with non-small cell lung cancer (NSCLC), according to observational study findings.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - October 5, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

New use for alcohol aversion drug in treatment of chemo resistant lung cancer found
(Trinity College Dublin) Scientists have had positive results from a laboratory-based study using a well-known alcohol aversion drug to try to combat chemotherapy resistance in the most common type of lung cancer, non-small cell lung cancer (NSCLC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2017 Category: Cancer & Oncology Source Type: news

Nivolumab cost effective for second-line treatment of NSCLC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2017 Category: Drugs & Pharmacology Source Type: news

A new approach to cancer drug discovery
Scientists at The Scripps Research Institute (TSRI) have developed and demonstrated a promising new strategy for the discovery of novel anti-cancer therapies. The TSRI scientists, collaborating with scientists at Pfizer, used their new approach to find small-molecule inhibitors of a protein that is important for the growth of non-small-cell lung cancers (NSCLCs). These cancers represent about 85 percent of lung cancers and are relatively insensitive to drug treatment. (Source: World Pharma News)
Source: World Pharma News - September 29, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

ASTRO: SBRT Prolongs Survival in Non - Small - Cell Lung Cancer
Trial stopped after significant improvement in progression - free survival in metastatic NSCLC (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 28, 2017 Category: Cancer & Oncology Tags: Oncology, Pulmonology, Radiology, Conference News, Source Type: news

ASTRO: Standard - Dose CRT Beats Higher Dose in Stage III NSCLC
Significantly improved five - year overall survival rates with 60 Gy chemoradiation tx versus high - dose (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 28, 2017 Category: Respiratory Medicine Tags: Oncology, Pulmonology, Radiology, Conference News, Source Type: news

Liquid Biopsy May Show Poor Prognosis in Early NSCLC (CME/CE)
(MedPage Today) -- No patient with detectable ctDNA after treatment lived 2 years (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 27, 2017 Category: General Medicine Source Type: news

Standard-Dose Radiation Therapy Confirmed in Advanced NSCLC Standard-Dose Radiation Therapy Confirmed in Advanced NSCLC
Mature 5-year follow-up data from the RTOG 0617 trial confirm that a dose of 60 Gy is superior to 74 Gy in advanced inoperable non-small cell lung cancer (NSCLC).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Radiation and Chemotherapy Together Boost Lung Cancer Survival
TUESDAY, Sept. 26, 2017 -- Combining radiation therapy with chemotherapy has substantially extended survival for many people with lung cancer, two new studies report. About 32 percent of non-small cell lung cancer patients who received... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 26, 2017 Category: General Medicine Source Type: news

RT Plus Chemo Triples PFS in Limited Metastatic Lung Cancer RT Plus Chemo Triples PFS in Limited Metastatic Lung Cancer
Adding consolidative radiotherapy to maintenance chemotherapy for patients with limited metastatic non-small cell lung cancer significantly improved progression-free survival (PFS).Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Local RT Triples PFS in Metastatic NSCLC (CME/CE)
(MedPage Today) -- Timing, pattern of treatment failure altered (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 25, 2017 Category: Hematology Source Type: news

AbbVie and BMS to investigate combination therapy in solid tumour trials
AbbVie and Bristol-Myers Squibb (BMS) have entered a clinical trial collaboration to assess ABBV-399 in combination with Opdivo (nivolumab) to treat patients with non-small-cell lung cancer (NSCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 24, 2017 Category: Pharmaceuticals Source Type: news

Radiation+immunotherapy can slow tumor growth for some patients with metastatic NSCLC
(American Society for Radiation Oncology) A new study involving patients with stage IV cancer finds that treatment with radiation therapy and immunotherapy can halt the growth of tumors by stimulating the body's immune system to attack the cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 24, 2017 Category: Cancer & Oncology Source Type: news

Adding radiation to chemotherapy may dramatically improve survival for advanced NSCLC
(American Society for Radiation Oncology) Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 24, 2017 Category: Cancer & Oncology Source Type: news

Long-term survival rates double previous estimates for locally advanced lung cancer
(American Society for Radiation Oncology) Long-term results of a phase III clinical trial indicate that survival rates for patients receiving chemoradiation for unresectable, locally advanced non-small cell lung cancer (NSCLC) may be more than twice as high as previous estimates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 24, 2017 Category: Cancer & Oncology Source Type: news

Roche receives EU approval of TECENTRIQ ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Roche today announced that the European Commission (EC) has granted a marketing authorisation for TECENTRIQ (atezolizumab) as a monotherapy for the treatment of people with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy regardless of PD-L1 status. (Source: Roche Media News)
Source: Roche Media News - September 22, 2017 Category: Pharmaceuticals Source Type: news

Roche receives EU approval of TECENTRIQ ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Roche today announced that the European Commission (EC) has granted a marketing authorisation for TECENTRIQ (atezolizumab) as a monotherapy for the treatment of people with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy regardless of PD-L1 status. (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2017 Category: Pharmaceuticals Source Type: news